Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
BMC Infect Dis ; 19(1): 218, 2019 Mar 04.
Article in English | MEDLINE | ID: mdl-30832593

ABSTRACT

BACKGROUND: Chlamydia trachomatis infections in women continue to be a major public health concern due to their high prevalence and consequent reproductive morbidities. While antibiotics are usually efficient to clear the Chlamydia, repeat infections are common and may contribute to pathological outcomes. Interferon-gamma (IFN-γ)-mediated immunity has been suggested to be protective against reinfection, and represent an important anti-chlamydial agent, primarily via the induction of indoleamine-2,3 dioxygenase 1 (IDO1) enzyme. IDO1 catalyzes the degradation of tryptophan, which can eliminate C. trachomatis infection in vitro. Here, we sought to measure IDO1 expression levels and related immune markers during different C. trachomatis infection statuses (repeated vs single infection vs post antibiotic treatment), in vitro and in vivo. METHODS: In this study, we measured the expression levels of IDO1 and immune regulatory markers, transforming growth factor ß1 (TGF-ß1) and forkhead box P3 (FoxP3), in vaginal swab samples of C. trachomatis-infected women, with either single or repeated infection. In addition, we used an in vitro co-culture model of endometrial carcinoma cell-line and peripheral blood mononuclear cells (PBMCs) to measure the same immune markers. RESULTS: We found that in women with repeated C. trachomatis infections vaginal IDO1 and TGF-ß1 expression levels were significantly increased. Whereas, women who cleared their infection post antibiotic treatment, had increased levels of IDO1 and TGF-ß1, as well as FoxP3. Similarly, using the in vitro model, we found significant upregulation of IDO1 and TGF-ß1 levels in the co-culture infected with C. trachomatis. Furthermore, we found that in PBMCs infected with C. trachomatis there was a significant upregulation in IDO1 levels, which was independent of IFN-γ. In fact, C. trachomatis infection in PBMCs failed to induce IFN-γ levels in comparison to the uninfected culture. CONCLUSIONS: Our data provide evidence for a regulatory immune response comprised of IDO1, TGF-ß1 and FoxP3 in women post antibiotic treatment. In this study, we demonstrated a significant increase in IDO1 expression levels in response to C. trachomatis infection, both in vivo and in vitro, without elevated IFN-γ levels. This study implicates IDO1 and TGF-ß1 as part of the immune response to repeated C. trachomatis infections, independently of IFN-γ.


Subject(s)
Chlamydia Infections/diagnosis , Indoleamine-Pyrrole 2,3,-Dioxygenase/metabolism , Interferon-gamma/metabolism , Transforming Growth Factor beta1/metabolism , Adult , Anti-Bacterial Agents/therapeutic use , Cell Line , Chlamydia Infections/drug therapy , Chlamydia Infections/microbiology , Chlamydia trachomatis/pathogenicity , Coculture Techniques , Female , Forkhead Transcription Factors/genetics , Forkhead Transcription Factors/metabolism , Humans , Indoleamine-Pyrrole 2,3,-Dioxygenase/genetics , Leukocytes, Mononuclear/cytology , Leukocytes, Mononuclear/metabolism , Recurrence , Transforming Growth Factor beta1/genetics , Up-Regulation , Vagina/metabolism , Vagina/microbiology , Young Adult
2.
Article in English | MEDLINE | ID: mdl-29404279

ABSTRACT

The natural course of Chlamydia trachomatis urogenital tract infections varies between individuals. While protective immunity can occur, some women can become reinfected, contributing to the development of severe pathology. While the reasons for these differences are unknown, an individual's response to induced interferon-γ (IFN-γ) is suggested to be critical. IFN-γ induction of the enzyme indoleamine 2,3-dioxygenase, which depletes tryptophan, may be the key. One hypothesis suggests that indole-producing bacteria in the vaginal microbiota can provide a substrate for the Chlamydia to synthesize tryptophan, rescuing the Chlamydia from host IFN-γ attack. We studied a cohort of 25 women who were either, Chlamydia negative, Chlamydia positive with a single infection, or Chlamydia positive with repeated infection, to test our hypothesis. We characterized their vaginal microbiota, cytokine response, as well as their tryptophan, kynurenine and indole concentrations directly in vaginal secretions. We found that C. trachomatis urogenital tract infections either initial or repeat infections, were associated with elevated vaginal kynurenine/tryptophan ratios, primarily as a result of elevated kynurenine levels. In addition, vaginal microbiota of community state type (CST) IV showed significantly lower vaginal tryptophan levels compared to CST I and III, which might be related to a higher abundance of indole producers found within this group. Furthermore, we found a higher abundance of indole producers in women who cleared their Chlamydia infection post antibiotic treatment. This study demonstrates for the first time in vivo, the association between high vaginal kynurenine/tryptophan ratios and C. trachomatis infections. In addition, tryptophan depletion was associated with vaginal microbiota of CST IV.


Subject(s)
Chlamydia Infections/metabolism , Chlamydia Infections/microbiology , Chlamydia trachomatis/physiology , Dysbiosis , Microbiota , Vagina/metabolism , Vagina/microbiology , Cytokines/metabolism , Female , Humans , Inflammation Mediators/metabolism , Kynurenine/metabolism , Metagenome , Metagenomics/methods , Tryptophan/metabolism
3.
BMC Microbiol ; 16(1): 286, 2016 Dec 03.
Article in English | MEDLINE | ID: mdl-27914477

ABSTRACT

BACKGROUND: The natural course of sexually transmitted infections caused by Chlamydia trachomatis varies between individuals. In addition to parasite and host effects, the vaginal microbiota might play a key role in the outcome of C. trachomatis infections. Interferon-gamma (IFN-γ), known for its anti-chlamydial properties, activates the expression of indoleamine 2,3-dioxygenase (IDO1) in epithelial cells, an enzyme that catabolizes the amino acid L- tryptophan into N-formylkynurenine, depleting the host cell's pool of tryptophan. Although C. trachomatis is a tryptophan auxotroph, urogenital strains (but not ocular strains) have been shown in vitro to have the ability to produce tryptophan from indole using the tryptophan synthase (trpBA) gene. It has been suggested that indole producing bacteria from the vaginal microbiota could influence the outcome of Chlamydia infection. RESULTS: We used two in vitro models (treatment with IFN-γ or direct limitation of tryptophan), to study the effects of direct rescue by the addition of exogenous indole, or by the addition of culture supernatant from indole-positive versus indole-negative Prevotella strains, on the growth and infectivity of C. trachomatis. We found that only supernatants from the indole-positive strains, P. intermedia and P. nigrescens, were able to rescue tryptophan-starved C. trachomatis. In addition, we analyzed vaginal secretion samples to determine physiological indole concentrations. In spite of the complexity of vaginal secretions, we demonstrated that for some vaginal specimens with higher indole levels, there was a link to higher recovery of the Chlamydia under tryptophan-starved conditions, lending preliminary support to the critical role of the IFN-γ-tryptophan-indole axis in vivo. CONCLUSIONS: Our data provide evidence for the ability of both exogenous indole as well as supernatant from indole producing bacteria such as Prevotella, to rescue genital C. trachomatis from tryptophan starvation. This adds weight to the hypothesis that the vaginal microbiota (particularly from women with lower levels of lactobacilli and higher levels of indole producing anaerobes) may be intrinsically linked to the outcome of chlamydial infections in some women.


Subject(s)
Chlamydia Infections/microbiology , Chlamydia trachomatis/metabolism , Indoles/metabolism , Interferon-gamma/deficiency , Prevotella/metabolism , Tryptophan/deficiency , Vaginal Diseases/microbiology , Chlamydia Infections/immunology , Chlamydia Infections/metabolism , Chlamydia trachomatis/genetics , Chlamydia trachomatis/immunology , Epithelial Cells/enzymology , Epithelial Cells/immunology , Epithelial Cells/metabolism , Epithelial Cells/microbiology , Female , HeLa Cells , Hep G2 Cells , Humans , In Vitro Techniques , Indoleamine-Pyrrole 2,3,-Dioxygenase/metabolism , Interferon-gamma/immunology , Kynurenine/analogs & derivatives , Kynurenine/metabolism , Microbiota , Prevotella/immunology , Prevotella/physiology , RNA, Messenger/genetics , RNA, Messenger/metabolism , Tryptophan/immunology , Tryptophan Synthase/genetics , Tryptophan Synthase/metabolism , Vaginal Diseases/immunology , Vaginal Diseases/metabolism
4.
Article in English | MEDLINE | ID: mdl-21876215

ABSTRACT

HIV clinicians today need to move from focusing on viral suppression to a chronic disease model in which comorbid conditions and risk factors are comprehensively identified and addressed to reduce rates of serious non-AIDS-related morbidity and mortality. This study aimed to determine the prevalence of comorbid conditions in an Australian HIV-positive population. Of 180 patients included, there was a median CD4 count of 0.520 cells/mm(3). The majority (88%) of patients were currently receiving highly active antiretroviral therapy (HAART). There were high rates of failure to attend clinical appointments (30%), current smoking (42%), hypertension (16%), and dyslipidemia (17%). Significant rates of dipstick-positive proteinuria (16%) and elevated blood glucose (15%) were recorded. Risk factors were commonly not addressed by the treating clinician. There is an urgent need to systematize detection and management of high-prevalence comorbid conditions to prevent premature mortality associated with serious non-AIDS events.


Subject(s)
HIV Infections/epidemiology , HIV-1 , Adult , Anxiety/epidemiology , CD4 Lymphocyte Count , Comorbidity , Comprehensive Health Care , Depression/epidemiology , Diabetes Mellitus/diagnosis , Diabetes Mellitus/epidemiology , Dyslipidemias/drug therapy , Dyslipidemias/epidemiology , Female , HIV Infections/drug therapy , HIV Infections/immunology , Hepatitis, Viral, Human/diagnosis , Hepatitis, Viral, Human/epidemiology , Humans , Hyperglycemia/epidemiology , Hypertension/drug therapy , Hypertension/epidemiology , Latent Tuberculosis/diagnosis , Male , Middle Aged , Osteoporosis/epidemiology , Patient Compliance , Prevalence , Proteinuria/epidemiology , Queensland/epidemiology , Retrospective Studies , Risk Factors , Sexually Transmitted Diseases/diagnosis , Sexually Transmitted Diseases/epidemiology , Smoking/epidemiology , Substance-Related Disorders/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...